Patient demographics and baseline characteristics (safety population)
| . | DFP (n = 152) . | DFO (n = 76) . | Overall (N = 228) . | DFP vs DFO P value* . |
|---|---|---|---|---|
| Age (y), n (%) | ||||
| ≥2 to <6 | 10 (6.6) | 2 (2.6) | 12 (5.3) | |
| ≥6 to <18 | 84 (55.3) | 46 (60.6) | 130 (57.0) | |
| ≥18 | 58 (38.1) | 28 (36.8) | 86 (37.7) | |
| Mean ± SD | 16.9 ± 10.2 | 16.9 ± 8.5 | 16.9 ± 9.6 | .9712 |
| Range | 3, 59 | 4, 40 | 3, 59 | |
| Sex, n (%) | .5740 | |||
| Female | 69 (45.4) | 38 (50.0) | 107 (46.9) | |
| Male | 83 (54.6) | 38 (50.0) | 121 (53.1) | |
| Ethnicity, n (%) | .7850 | |||
| African or African American | 7 (4.6) | 7 (9.2) | 14 (6.1) | |
| Arab or Egyptian | 18 (11.8) | 6 (7.9) | 24 (10.5) | |
| Caucasian | 100 (65.8) | 49 (64.5) | 149 (65.4) | |
| Hispanic/Latino | 10 (6.6) | 6 (7.9) | 16 (7.0) | |
| Other† | 17 (11.2) | 8 (10.5) | 25 (11.0) | |
| Race, n (%) | .6632 | |||
| Black | 23 (15.1) | 14 (18.4) | 37 (16.2) | |
| Multiracial | 9 (5.9) | 6 (7.9) | 15 (6.6) | |
| White | 120 (78.9) | 56 (73.7) | 176 (77.2) | |
| Transfusional iron input (mg/kg per day) in the 3 mo before study | ||||
| N | 152 | 76 | N/A | |
| Mean (SD) | 0.18 (0.15) | 0.20 (0.18) | N/A | .5442 |
| Range | 0.00, 1.15 | 0.00, 1.13 | N/A | |
| Primary diagnosis,n (%) | .8313 | |||
| Autoimmune hemolytic anemia | 1 (0.7) | 1 (1.3) | 2 (0.9) | |
| Congenital anemia | 1 (0.7) | 1 (1.3) | 2 (0.9) | |
| Congenital dyserythropoietic anemia | 4 (2.6) | 3 (3.9) | 7 (3.1) | |
| Hemoglobin C disease | 2 (1.3) | 1 (1.3) | 3 (1.3) | |
| Hemoglobinopathy | 1 (0.7) | 0 (0.0) | 1 (0.4) | |
| Hemolytic anemia | 1 (0.7) | 0 (0.0) | 1 (0.4) | |
| Pyruvate kinase deficiency anemia | 2 (1.3) | 1 (1.3) | 3 (1.3) | |
| Sickle cell disease‡ | 126 (82.9) | 63 (82.9) | 189 (82.9) | |
| Spherocytic anemia§ | 14 (9.2) | 6 (7.9) | 20 (8.8) | |
| Previous iron chelation therapy,ǁn (%) | ||||
| Deferiprone | 28 (18.4) | 19 (25.0) | 47 (20.6) | .2975 |
| Deferoxamine | 25 (16.4) | 17 (22.4) | 42 (18.4) | .2825 |
| Deferasirox | 38 (25.0) | 17 (22.4) | 55 (24.1) | .7436 |
| No iron chelation therapy | 74 (48.7) | 32 (42.1) | 106 (46.5) | .3988 |
| . | DFP (n = 152) . | DFO (n = 76) . | Overall (N = 228) . | DFP vs DFO P value* . |
|---|---|---|---|---|
| Age (y), n (%) | ||||
| ≥2 to <6 | 10 (6.6) | 2 (2.6) | 12 (5.3) | |
| ≥6 to <18 | 84 (55.3) | 46 (60.6) | 130 (57.0) | |
| ≥18 | 58 (38.1) | 28 (36.8) | 86 (37.7) | |
| Mean ± SD | 16.9 ± 10.2 | 16.9 ± 8.5 | 16.9 ± 9.6 | .9712 |
| Range | 3, 59 | 4, 40 | 3, 59 | |
| Sex, n (%) | .5740 | |||
| Female | 69 (45.4) | 38 (50.0) | 107 (46.9) | |
| Male | 83 (54.6) | 38 (50.0) | 121 (53.1) | |
| Ethnicity, n (%) | .7850 | |||
| African or African American | 7 (4.6) | 7 (9.2) | 14 (6.1) | |
| Arab or Egyptian | 18 (11.8) | 6 (7.9) | 24 (10.5) | |
| Caucasian | 100 (65.8) | 49 (64.5) | 149 (65.4) | |
| Hispanic/Latino | 10 (6.6) | 6 (7.9) | 16 (7.0) | |
| Other† | 17 (11.2) | 8 (10.5) | 25 (11.0) | |
| Race, n (%) | .6632 | |||
| Black | 23 (15.1) | 14 (18.4) | 37 (16.2) | |
| Multiracial | 9 (5.9) | 6 (7.9) | 15 (6.6) | |
| White | 120 (78.9) | 56 (73.7) | 176 (77.2) | |
| Transfusional iron input (mg/kg per day) in the 3 mo before study | ||||
| N | 152 | 76 | N/A | |
| Mean (SD) | 0.18 (0.15) | 0.20 (0.18) | N/A | .5442 |
| Range | 0.00, 1.15 | 0.00, 1.13 | N/A | |
| Primary diagnosis,n (%) | .8313 | |||
| Autoimmune hemolytic anemia | 1 (0.7) | 1 (1.3) | 2 (0.9) | |
| Congenital anemia | 1 (0.7) | 1 (1.3) | 2 (0.9) | |
| Congenital dyserythropoietic anemia | 4 (2.6) | 3 (3.9) | 7 (3.1) | |
| Hemoglobin C disease | 2 (1.3) | 1 (1.3) | 3 (1.3) | |
| Hemoglobinopathy | 1 (0.7) | 0 (0.0) | 1 (0.4) | |
| Hemolytic anemia | 1 (0.7) | 0 (0.0) | 1 (0.4) | |
| Pyruvate kinase deficiency anemia | 2 (1.3) | 1 (1.3) | 3 (1.3) | |
| Sickle cell disease‡ | 126 (82.9) | 63 (82.9) | 189 (82.9) | |
| Spherocytic anemia§ | 14 (9.2) | 6 (7.9) | 20 (8.8) | |
| Previous iron chelation therapy,ǁn (%) | ||||
| Deferiprone | 28 (18.4) | 19 (25.0) | 47 (20.6) | .2975 |
| Deferoxamine | 25 (16.4) | 17 (22.4) | 42 (18.4) | .2825 |
| Deferasirox | 38 (25.0) | 17 (22.4) | 55 (24.1) | .7436 |
| No iron chelation therapy | 74 (48.7) | 32 (42.1) | 106 (46.5) | .3988 |
DFO, deferoxamine; DFP, deferiprone; N/A, not available.
t test for age; Fisher exact test for sex, ethnicity, race, primary diagnosis, and previous iron chelation therapy.
Other ethnicities include black British, non-Hispanic, and unknown.
Sickle cell disease includes classifications of sickle cell disease, sickle cell anemia, and thalassemia sickle cell.
Spherocytic anemia includes classifications of hereditary spherocytosis and spherocytic anemia.
Iron chelation therapy within 3 mo before baseline.